Detailed Narrative
Strong Financial Performance and Strategic Repositioning
Granules India delivered robust financial results in Q4 and FY26, with full-year revenue reaching ₹53,656 million, a 20% YoY increase. Q4 revenue grew 23% YoY to ₹14,706 million. The company's EBITDA for FY26 stood at ₹11,851 million, up 25% YoY, with margins expanding to 22.1%. This performance reflects a year of deliberate reset, stabilizing operations, strengthening execution, and making clear strategic choices for value-led growth, including a shift towards more complex and differentiated products.
Peptide CDMO Business Turns Profitable
The acquisition of Senn Chemicals proved strategic, with the Peptide CDMO segment turning EBITDA positive in Q4 FY26. This segment contributed ₹1,593 million to FY26 revenue, representing 3% of the total. Management highlighted that the business is now more execution-led and operationally aligned, with a clear objective to achieve PAT positive performance on an annual basis from FY27, despite potential quarter-to-quarter variations inherent in a project-driven CDMO model. Investments are ongoing to expand peptide API capacity in Zurich and intermediates manufacturing in India.
Debt Reduction and Capital Deployment
The company significantly reduced its net debt to ₹4,021 million from ₹7,061 million in FY25, improving the net debt to EBITDA ratio to 0.34x from 0.75x. This reduction was largely supported by an additional equity infusion of ₹6,656 million during FY26. For FY27, Granules plans a capex in the range of ₹600 million, with over ₹200 million allocated specifically for a new distribution center in the U.S. Other capex areas include a new API facility and IT infrastructure, with net debt expected to remain flattish or see a slight increase.
Regulatory Compliance and Gagillapur Remediation
Granules continued to prioritize quality and compliance, with remediation activities at Gagillapur progressing materially. The post-warning letter engagement with the U.S. FDA was completed in January, and all action point responses were submitted in February. While the company states it is ready for an FDA audit, the timeline for a re-inspection remains uncertain as it depends on the FDA's schedule. Other facilities, including GLS and GCH, successfully completed regulatory inspections with positive outcomes.
Controlled Substances and DCDA Pipeline
Granules has strengthened its position in the controlled substances space, ranking 4th among U.S. generics companies. The company aims to launch 1-2 new controlled substance products annually over the next 2-3 years, with revenue from finished dosages expected in 1-2 years and APIs sooner. The DCDA project in Vizag is nearing commercialization, with the pilot stage expected to wrap up in 2-2.5 months, followed by equipment ordering for a commercial plant estimated to cost around ₹200 million. However, Chinese competition has led to drastic price reductions, posing a challenge.
External Headwinds and Margin Outlook
The company acknowledged ongoing external cost pressures from increased raw material, packing material, and freight prices. While Granules aims to pass on these increases, the market uncertainty🌐 makes it difficult to provide precise gross margin clarity for FY27. Despite these headwinds, the company's gross margin expanded to 65% in FY26 and 65.7% in Q4, driven by a sustained shift towards complex generics and higher contributions from the Peptide CDMO business.